HOUSE_OVERSIGHT_024822.jpg
1.69 MB
Extraction Summary
12
People
4
Organizations
3
Locations
0
Events
1
Relationships
2
Quotes
Document Information
Type:
Financial research report (table of contents)
File Size:
1.69 MB
Summary
This document is the Table of Contents for a 'Cowen Collaborative Insights' research report dated February 25, 2019, focusing on the CBD and Cannabis market. The report covers various sectors including consumer products, healthcare, and global landscapes, with sections attributed to specific analysts (e.g., Azer, Nadeau, Schenkel). The document bears a 'HOUSE_OVERSIGHT_024822' Bates stamp, indicating it is part of a document production to the House Oversight Committee, likely related to investigations into financial records.
People (12)
| Name | Role | Context |
|---|---|---|
| Michael Cella | Recipient |
Email address listed in the sidebar watermark: michael.cella@cowen.com
|
| Azer | Author/Analyst |
Listed as author for Consumer Products Market Sizing, Consumer Products Opportunities, The CBD Competitive Landscape,...
|
| Nadeau | Author/Analyst |
Listed as author for The Science Of CBD, Additional Applications, and Epilepsy & Psychiatric Conditions
|
| Neivert | Author/Analyst |
Listed as author for CBD Hemp Cultivation
|
| Schenkel | Author/Analyst |
Listed as author for Synthetic Cannabis and Life Science Tools Participation
|
| Rhyee | Author/Analyst |
Listed as author for Health Care Perspectives (Drug Retailer, Payor, Provider)
|
| Blackledge | Author/Analyst |
Listed as author for eCommerce section
|
| Chen | Author/Analyst |
Listed as author for Cannabidiol Entrance Into Mass Retail section
|
| Kernan | Author/Analyst |
Listed as author for Growing Application For Hemp And CBD Within The Apparel & Footwear Market
|
| Charles | Author/Analyst |
Listed as author for section regarding Starbucks
|
| Assaraf | Author/Analyst |
Listed as author for Regulatory Considerations section (Washington Research Group)
|
| Osborne | Author/Analyst |
Listed as author for Additional Applications and Industrial Hemp sections
|
Organizations (4)
| Name | Type | Context |
|---|---|---|
| Cowen |
Publisher of the report (Cowen Collaborative Insights)
|
|
| Starbucks |
Subject of analysis regarding piloting CBD oil
|
|
| Washington Research Group |
Affiliated with author Assaraf
|
|
| House Oversight Committee |
Implied by the Bates stamp 'HOUSE_OVERSIGHT_024822'
|
Locations (3)
| Location | Context |
|---|---|
|
Mentioned in 'Canadian LP Commentary on CBD'
|
|
|
Mentioned in 'European Landscape'
|
|
|
Mentioned in 'Latin American Landscape'
|
Relationships (1)
Email address is michael.cella@cowen.com
Key Quotes (2)
"We Would Expect Starbucks To Be First Under Our Active Coverage To Pilot CBD Oil, Though Not In Near Term Plan"Source
HOUSE_OVERSIGHT_024822.jpg
Quote #1
"This report is intended for michael.cella@cowen.com. Unauthorized redistribution of this report is prohibited."Source
HOUSE_OVERSIGHT_024822.jpg
Quote #2
Full Extracted Text
Complete text extracted from the document (7,053 characters)
COWEN
COLLABORATIVE INSIGHTS
February 25, 2019
COLLABORATIVE INSIGHTS
February 25, 2019
TABLE OF CONTENTS
Consumer Products Market Sizing (Azer) ........................................................................................................................................................ 8
The Science Of CBD (Nadeau) ............................................................................................................................................................................. 10
CBD Hemp Cultivation (Neivert)......................................................................................................................................................................... 11
Synthetic Cannabis (Schenkel) ........................................................................................................................................................................... 17
Life Science Tools Participation In The Legal Cannabis Market (Schenkel) ............................................................................................. 22
Consumer Products Opportunities (Azer) ....................................................................................................................................................... 24
Nutraceuticals ..................................................................................................................................................................................................... 28
Topicals ................................................................................................................................................................................................................. 35
Beverages .............................................................................................................................................................................................................. 38
Bottled Water ...................................................................................................................................................................................................... 39
Energy Drinks ...................................................................................................................................................................................................... 40
Beer ........................................................................................................................................................................................................................ 41
Beauty ................................................................................................................................................................................................................... 44
Food (Confections) ............................................................................................................................................................................................. 49
Vapor ...................................................................................................................................................................................................................... 51
The CBD Competitive Landscape – Public/Private Company Discussions (Azer) ................................................................................. 54
Publicly Traded Companies .............................................................................................................................................................................. 54
Canadian LP Commentary on CBD ................................................................................................................................................................. 57
Benchmarking ..................................................................................................................................................................................................... 58
Private Companies .............................................................................................................................................................................................. 61
Health Care: Drug Retailer Perspective (Rhyee)........................................................................................................................................... 63
Health Care: Payor Perspective (Rhyee)......................................................................................................................................................... 64
Health Care: Provider Perspective (Rhyee).................................................................................................................................................... 64
eCommerce To Be A Key Consumer Distribution Channel Long Term (Blackledge) ............................................................................. 65
Cannabidiol (CBD) Entrance Into Mass Retail May Start In Beauty Before Entering Broadlines (Chen).......................................... 69
Growing Application For Hemp And CBD Within The Apparel & Footwear Market (Kernan) ............................................................ 70
We Would Expect Starbucks To Be First Under Our Active Coverage To Pilot CBD Oil, Though Not In Near Term Plan (Charles) ............. 74
Regulatory Considerations For CBD (Assaraf – Washington Research Group) ....................................................................................... 75
Global CBD Landscape (Azer)............................................................................................................................................................................. 79
European Landscape .......................................................................................................................................................................................... 80
Latin American Landscape ............................................................................................................................................................................... 84
Additional Applications / Implications (Nadeau & Osborne)...................................................................................................................... 87
Epilepsy & Psychiatric Conditions (Nadeau) ................................................................................................................................................ 87
Industrial Hemp And Sustainable Bioproducts (Osborne) ........................................................................................................................ 94
Appendix.................................................................................................................................................................................................................. 96
The Science Of CBD (Nadeau) ............................................................................................................................................................................. 10
CBD Hemp Cultivation (Neivert)......................................................................................................................................................................... 11
Synthetic Cannabis (Schenkel) ........................................................................................................................................................................... 17
Life Science Tools Participation In The Legal Cannabis Market (Schenkel) ............................................................................................. 22
Consumer Products Opportunities (Azer) ....................................................................................................................................................... 24
Nutraceuticals ..................................................................................................................................................................................................... 28
Topicals ................................................................................................................................................................................................................. 35
Beverages .............................................................................................................................................................................................................. 38
Bottled Water ...................................................................................................................................................................................................... 39
Energy Drinks ...................................................................................................................................................................................................... 40
Beer ........................................................................................................................................................................................................................ 41
Beauty ................................................................................................................................................................................................................... 44
Food (Confections) ............................................................................................................................................................................................. 49
Vapor ...................................................................................................................................................................................................................... 51
The CBD Competitive Landscape – Public/Private Company Discussions (Azer) ................................................................................. 54
Publicly Traded Companies .............................................................................................................................................................................. 54
Canadian LP Commentary on CBD ................................................................................................................................................................. 57
Benchmarking ..................................................................................................................................................................................................... 58
Private Companies .............................................................................................................................................................................................. 61
Health Care: Drug Retailer Perspective (Rhyee)........................................................................................................................................... 63
Health Care: Payor Perspective (Rhyee)......................................................................................................................................................... 64
Health Care: Provider Perspective (Rhyee).................................................................................................................................................... 64
eCommerce To Be A Key Consumer Distribution Channel Long Term (Blackledge) ............................................................................. 65
Cannabidiol (CBD) Entrance Into Mass Retail May Start In Beauty Before Entering Broadlines (Chen).......................................... 69
Growing Application For Hemp And CBD Within The Apparel & Footwear Market (Kernan) ............................................................ 70
We Would Expect Starbucks To Be First Under Our Active Coverage To Pilot CBD Oil, Though Not In Near Term Plan (Charles) ............. 74
Regulatory Considerations For CBD (Assaraf – Washington Research Group) ....................................................................................... 75
Global CBD Landscape (Azer)............................................................................................................................................................................. 79
European Landscape .......................................................................................................................................................................................... 80
Latin American Landscape ............................................................................................................................................................................... 84
Additional Applications / Implications (Nadeau & Osborne)...................................................................................................................... 87
Epilepsy & Psychiatric Conditions (Nadeau) ................................................................................................................................................ 87
Industrial Hemp And Sustainable Bioproducts (Osborne) ........................................................................................................................ 94
Appendix.................................................................................................................................................................................................................. 96
This report is intended for michael.cella@cowen.com. Unauthorized redistribution of this report is prohibited.
6 COWEN.COM
HOUSE_OVERSIGHT_024822
HOUSE_OVERSIGHT_024822
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document